Related Experiment Video
Updated: Jul 11, 2026
03:47
Enhancement of Facial Rejuvenation Through a Combination of 1565 nm Non-Ablative Fractional Laser with 30% Supramolecular Salicylic Acid
Published on: September 27, 2024
New products and regimens (since 2003).
1West London Menopause & PMS Centre, London, UK.
Climacteric : the Journal of the International Menopause Society
|October 27, 2007
Summary
Hormone replacement therapy (HRT) use has stabilized, with new low-dose and transdermal options offering symptom relief and bone protection while minimizing risks. Novel progestogens and non-hormonal treatments are also emerging for menopause management.
Area of Science:
- Gynecology
- Endocrinology
- Pharmacology
Background:
- Hormone replacement therapy (HRT) use declined significantly after the Women's Health Initiative and Million Women studies.
- Despite past concerns, HRT remains important for managing menopausal symptoms and preventing osteoporosis.
- Pharmaceutical industry decisions impact product availability and development, necessitating innovation in HRT.
Purpose of the Study:
- To review recent advancements in hormone replacement therapy products.
- To highlight new formulations and non-hormonal alternatives for menopausal symptom management.
- To assess the balance of benefits and risks associated with emerging HRT options.
Main Methods:
- Review of current literature and clinical trial data on new HRT products.
- Analysis of novel oral and transdermal estrogen preparations.
- Evaluation of new progestogen formulations, androgen therapy, and non-hormonal treatments.
Main Results:
- Low- and ultra-low-dose oral estrogens (conjugated equine estrogens, estradiol) show efficacy for symptom relief and osteoporosis prevention with reduced side effects.
- A 14 microg transdermal estrogen system provides bone protection without requiring endometrial protection.
- New progestogens (drospirenone, bioidentical progesterone, SERMs) mitigate progestogenic side effects; a female androgen patch is available for hypoactive sexual desire disorder.
Conclusions:
- New HRT formulations offer improved safety profiles and efficacy for menopausal symptom management and bone health.
- Emerging non-hormonal treatments, like desvenlafaxine succinate, and combination therapies provide additional options for women.
- Continued innovation in HRT aims to optimize therapeutic benefits while minimizing risks for postmenopausal women.
Related Concept Videos
01:28Drug Products: Biologics, Biosimilars and Interchangeables
Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
01:29Clinically Relevant Drug Product Specifications: Methods of Establishment
Product specifications define the acceptable quality of a pharmaceutical product by ensuring identity, purity, potency, and strength. These specifications serve as benchmarks during development, manufacturing, and post-approval quality control. Clinically relevant specifications are particularly important because they directly relate to a drug's safety and efficacy in clinical use.Dissolution studies are critical biopharmaceutic tools that link in vitro behavior to in vivo performance. They...
01:24Dosage Regimen: Individualization
Individualization in dosing regimens is the customization of medication doses for individual patients. Its necessity arises from the goal of maximizing therapeutic benefits while minimizing risks. This approach is pivotal because human responses to drugs can vary widely; what is effective for one person may be inadequate or excessive for another. Interpatient (intersubject) variability refers to differences in drug responses between individuals, while intrapatient (intrasubject) variability...
01:25Drug Regulation
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
01:27Acne Infection
Acne is a multifactorial skin condition primarily affecting adolescents and young adults, with a global prevalence estimated to exceed 75% in this demographic. The condition is characterized by the formation of comedones (blackheads and whiteheads), papules, pustules, nodules, and, in severe cases, cysts, particularly in areas rich in sebaceous glands such as the face, neck, chest, and back. The pathogenesis involves increased sebum production, follicular hyperkeratinization, colonization by...
01:28Dosage Regimens: Designs and Approaches
Designing a dosage regimen, which refers to the manner of drug administration, is a complex process involving the selection of drug dose, route, and frequency. This process is underpinned by pharmacokinetic parameters derived from tests and population averages. These parameters are then tailored to patient-specific variables such as diagnosis, demographics, and allergy status. Once therapy commences, therapeutic response monitoring is critical and achieved through clinical and physical...